Evidence map›Paper›PMID 37696513›Full record

ArticleThe American journal of tropical medicine and hygiene2023

Integrated Prevalence Assessment of Wuchereria bancrofti and Onchocerca volvulus in Three Co-Endemic Districts of Gambella Region, Ethiopia.

Mohammed Hassen, Aderajew Mohammed, Tekola Endeshaw, Tewodros Seid, Fikresilasie Samuel, Tadese Asmare, Henok Birhanu, Firdaweke Bekele, Adane Yayeh, Fikre Seife and 7 more

Open access · hybridAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Mohammed HassenThe Carter Center, Addis Ababa, Ethiopia.
Aderajew MohammedThe Carter Center, Addis Ababa, Ethiopia.
Tekola EndeshawThe Carter Center, Addis Ababa, Ethiopia.
Tewodros SeidThe Carter Center, Addis Ababa, Ethiopia.
Fikresilasie SamuelThe Carter Center, Addis Ababa, Ethiopia.
Tadese AsmareThe Carter Center, Addis Ababa, Ethiopia.
Henok BirhanuThe Carter Center, Addis Ababa, Ethiopia.
Firdaweke BekeleThe Carter Center, Addis Ababa, Ethiopia.
Adane YayehThe Carter Center, Addis Ababa, Ethiopia.
Fikre SeifeFederal Ministry of Health, Addis Ababa, Ethiopia.
Mossie TamiruFederal Ministry of Health, Addis Ababa, Ethiopia.
Kadu MeriboFederal Ministry of Health, Addis Ababa, Ethiopia.
Zerihun TadesseThe Carter Center, Addis Ababa, Ethiopia.
Emily GriswoldThe Carter Center, Atlanta, Georgia.
Moses KatabarwaThe Carter Center, Atlanta, Georgia.
Frank RichardsThe Carter Center, Atlanta, Georgia.
Gregory S NolandThe Carter Center, Atlanta, Georgia.
The Carter Center · ETCarter Center · USFederal Ministry of Health · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphatic filariasis (LF) and onchocerciasis (OV) are among the neglected tropical diseases (NTD) targeted for elimination in Ethiopia. We used a transmission assessment survey (TAS-1) to evaluate the serological status of OV in three co-endemic districts in Gambella simultaneously. During May and June 2019, blood samples were collected from 6- to 7-year-old children who were randomly selected through standard community-based TAS methodology. Children were tested for both circulating filarial antigen (CFA) for LF via filariasis test strip and for Onchocerca volvulus 16 (Ov16) antibody for OV via laboratory-based ELISA. A total of 3,377 children from 150 villages in the three districts were tested; 1,823 (54.0%) were male. All three districts had CFA results below the critical threshold for stopping LF mass drug administration (MDA). In contrast, 40 children (1.2%) were positive for Ov16 antibody, well above the WHO's OV stop MDA threshold of 0.1%. The integrated assessment indicated two programmatic decisions: stop MDA for LF and continue MDA for OV. Accordingly, albendazole MDA was discontinued in the districts but ivermectin MDA continued. This integrated assessment showed that a random sample for TAS can give important information about OV transmission status in co-endemic areas.

Indexed as

Elephantiasis, FilarialOnchocerca volvulusAlbendazoleAnimalsAntigens, HelminthChildEthiopiaFemaleHumansIvermectinMaleNeglected DiseasesPrevalenceWuchereria bancroftiAlbendazoleAntigens, HelminthIvermectin

Identifiers

PMID37696513
PMCPMC10551079
OpenAlexW4386600775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.